Verapamil reduces dipyridamole-induced myocardial ischemia in patients with coronary artery disease

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 3, 1999, Pages 383-387

  Ferrara, Nicola ^a,b   Longobardi, Giancarlo ^a   Leosco, Dario ^b   Rosiello, Renato ^a   Abete, Pasquale ^b   Cacciatore, Francesco ^b   Guerra, Nunzio ^a   Furgi, Giuseppe ^a   Rengo, Franco ^a,b  

^a IRCCS   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Coronary artery disease; Dipyridamole; Verapamil

Indexed keywords

DIPYRIDAMOLE; PLACEBO; VERAPAMIL;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CLINICAL ARTICLE; COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEMODYNAMIC MONITORING; HUMAN; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AGED; CALCIUM CHANNEL BLOCKERS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DIPYRIDAMOLE; ECHOCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; VASODILATOR AGENTS; VERAPAMIL;

EID: 0032994230     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199903000-00006     Document Type: Article

References (34)

1. Ferrara N, Bonaduce D, Leosco D, et al. Two-dimensional echocardiographic evaluation of ventricular asynergy by dipyridamole: correlation with thallium scanning. Clin Cardiol 1986;9:437-42.
2. Picano E, Distante A, Masini M, Morales MA, Lattanzi F, L'Abbate A. Dipyridamole-echocardiography test in effort angina pectoris. Am J Cardiol 1985;56:452-6.
3. Picano E. Dipyridamole-echocardiography test: historical background and physiologic basis. Eur Heart J 1989;10:365-76.
4. Lattanzi F, Picano E, Bolognese L, et al. Inhibition of dipyridamole-induced ischemia by antianginal therapy in humans. Correlation with exercise electrocardiography. Circulation 1991;83:1256-62.
5. Ferrara N, Longobardi G, Nicolino A, et al. Effect of beta-adrenoceptor blockade on dipyridamole induced myocardial asynergies in coronary artery disease. Am J Cardiol 1992;70:724-7.
6. Longobardi G, Ferrara N, Leosco D, et al. Failure of protective effect of captopril and enalapril on exercise and dipyridamole-induced myocardial ischemia. Am J Cardiol 1995;76:255-8.
7. Picano E, Marraccini P, Lattanzi F, et al. Dipyridamole-echocardiography test as a clue for assessing the organic "ceiling" of indi-vidual coronary reserve. Eur Heart J 1987;8:38-44.
8. Nayler WG. Calcium antagonists and the ischemic myocardium. Int J Cardiol 1987;15:267-85.
9. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian study (CRIS). Am J Cardiol 1996; 77:365-9.
10. Bayer R, Kalusche D, Kaufmann R, Mannhold R. Inotropic and electrophysiological actions of verapamil and D-600 in mammalian myocardium III. Effects of the optical isomers on the transmembrane action potentials. Arch Pharmacol 1975;290:81-90.
11. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomie function in human hypertension. Hypertension 1995;26:143-9.
12. Bonow RO, Leon MB, Rosing DR, Kent KM, Lipson LC. Effects of verapamil and propranolol on left ventricular systolic function and diastolic function and diastolic filling in patients with coronary artery disease: radionuclide angiographic studies at rest and during exercise. Circulation 1982;65:1337-50.
13. Kostuk WJ, Pflugfelder P. Comparative effects of calcium entry-blocking drugs, β-blocking drugs and their combination in patients with chronic stable angina. Circulation 1987;75(suppl V):114-26.
14. Rehnqvist N, Hjemdahl P, Billing E, et al. Effect of metoprolol vs verapamil in patients with stable angina pectoris. Eur Heart J 1996;17:76-81.
15. Johnson SM, Mauritson DR, Willerson JT, Hillis LD. A controlled trial of verapamil for Prinzmetal's variant angina. N Engl J Med 1981;304:862-6.
16. The Danish Study Group on Verapamil in Myocardial Infarction. The effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II, DAVIT-II). Am J Cardiol 1990;66:779-85.
17. Marino P, Zanolla L, Zardini P. Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI trial. J Am Coll Cardiol 1989;14:1149-58.
18. GISSI 2. Sottoprogetto ischemia residua. G Ital Cardiol 1988;18: 758-63.
19. Marangelli V, D'Ambrosio G, Carella L, Iliceto S, Rizzon P. Digital cine-loop technology: a new tool for the evaluation of wall motion abnormalities. In: Iliceto S, Rizzon P, Roelandt JRTC, eds. Ultrasound in coronary artery disease: present role and future perspectives. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1991:145-58.
20. Buhler FR, Hulthen UL, Kiowski W, Muller FB, Bolli P. The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol 1982;4(suppl 3):S350-7.
21. Leonetti G, Cuspidi C, Sampieri L, Terzoli L, Zanchetti A. Comparison of cardiovascular, renal, and humoral effects of acute administration of the calcium channel blockers in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 1982;4(suppl 3): S319-24.
22. Chambers CE, Brown KA. Dipyridamole-induced ST segment depression during thallium-201 imaging in patients with coronary artery disease: angiographic and hemodynamic determinants. J Am Coll Cardiol 1988;12(1):37-41.
23. Matsuzaki M, Gallagher KP, Patritti J, et al. Effects of a calcium-entry blocker (diltiazem) on regional myocardial flow and function during exercise in conscious dogs. Circulation 1984;69(4):801-14.
24. Chew CY, Brown BG, Singh BN, Wong MM, Pierce C, Petersen R. Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action. Am J Cardiol 1983;51(5):699-705.
25. Da Luz PL, De Barros LFM, Leite JJ, Pileggi F, Decourt LV. Effect of verapamil on regional coronary and myocardial perfusion during acute coronary occlusion. Am J Cardiol 1980;45:269-77.
26. Brown BG, Bolson EL, Dodge HT. Dynamic mechanisms in human coronary stenosis. Circulation 1984;70:917-22.
27. Lucarini AR, Picano E, Marini C, Favilla S, Salvetti A, Distante A. Activation of sympathetic tone during dipyridamole test. Chest 1992;102:444-7.
28. Robertson D, Johnson GA, Robertson RM, Nies AS, Shand DG, Oates JA. Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation 1979;59: 637-43.
29. Meyer EC, Sommers DK, Avenant JC. The effect of verapamil on cardiac sympathetic function. Eur J Clin Pharmacol 1991;41: 517-9.
30. Johnson RH, Spalding JMK. Disorders of the autonomic nervous system. Philadelphia: Blackwell Scientific Publications, 1974:1-22.
31. Gurtu S, Seth S, Roychoudhary AK. Evidence for verapamil-induced functional inhibition of noradrenergic neurotransmission in vitro. Naunyn Schmiedebergs Arch Pharmacol 1992;345:172-5.
32. Liu HQ, Dun NJ. Effect of verapamil on synaptic transmission in mammalian sympathetic ganglia. Chung Kuo Yao Li Hsueh Pao 1990;11:415-8.
33. Barringer DL, Bunag RD. Differential age-dependent attenuation of reflex tachycardia by verapamil in rats. Mech Ageing Dev 1991;58:111-25.
34. Doran AR, Narang PK, Meigs CY, et al. Verapamil concentrations in cerebrospinal fluid after oral administration [Letter]. N Engl J Med 1985;312:1261-2.